CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
Plenty of investors are drawn to the idea of blue chip names because they seem more secure and could produce more reliable growth.
The RBA governor has suggested that the central bank may not cut interest rates further. What would this mean for ASX shares?
The CSL Limited (ASX:CSL) share price hit a new all-time high today following the company’s annual general meeting (AGM). Is it time to buy CSL shares?
Shares in CSL Limited (ASX: CSL) hit a new all time high today and may well be the best healthcare stock on the ASX.
Healthcare companies around the world right now have tailwinds and competitive advantages pushing their growth. The BetaShares Global Healthcare ETF (ASX: DRUG) wants to take advantage of that.
Most Australian investors have a large exposure to financial companies and banks which can make a basic ASX 200 ETF look unappealing. Could the BetaShares Australian EX-20 Portfolio Diversifier ETF (ASX: EX20) be the solution?
If the Australian dollar continues to fall against the US dollar, I think it’s worth looking at shares of CSL Limited (ASX: CSL), Cochlear Limited (ASX: COH) and Altium Limited (ASX: ALU).
Would it be a good idea to buy $1,000 of Westpac Banking Corp (ASX:WBC) shares?
There are several ASX ETFs designed to track the S&P/ASX 200 (INDEXASX: XJO) but only one to track the top 50 companies on the ASX. How does the SPDR S&P/ASX 50 Fund (ASX: SFY) compare?
